SINOPHARM : Announcements and Notices - Announcement Principal Financial Data of Sinopharm Accord for the Nine Months Ended 30 September 2017

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099) ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2017

Reference is made to the overseas regulatory announcement dated 25 October 2017 (the "Announcement") and issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the third quarterly report for the nine months ended 30 September 2017 of China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares; 200028 for B shares).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Sinopharm Accord for the nine months ended 30 September 2017 as set out in the Announcement.

PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD

Unit: Yuan Currency: RMB

Whether it has retroactive adjustment or re-statement on previous accounting data or not

√ Yes □ No

Reasons of retroactive adjustment or restatement Enterprise combined under the same control

Current period-end	Period-end of last year		Increase/ decrease
	Before adjustment	After adjustment	After adjustment
Total assets	23,155,826,581.90	21,312,754,511.97	21,316,548,247.95	8.63%
Net assets attributable to shareholders of listed company	9,109,326,014.78	8,450,150,621.93	8,452,426,863.52	7.77%
Current period	Increase/ decrease in comparison with same period of last year	Year-begin to end of the Period	Increase/ decrease in comparison with year-begin to Period-end of last year
Operating revenue	10,753,911,112.98	1.96%	31,278,718,782.55	0.54%
Net profit attributable to shareholders of the listed company	246,977,990.75	-1.24%	803,103,308.94	-11.67%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	244,923,007.75	41.78%	791,176,397.75	37.71%
Net cash flow arising from operating activities	--	--	511,083,437.88	-38.30%
Basic earnings per share (RMB/Share)	0.577	-2.37%	1.876	-12.70%
Diluted earnings per share (RMB/Share)	0.577	-2.37%	1.876	-12.70%
Weighted average ROE	2.75%	-0.36%	9.15%	-2.54%

Note: In October 2016, Sinopharm Accord Group sold the 51% equity of subordinate three pharmaceutical industry subsidiaries respectively (including Zhijun Pharmaceutical, Zhijun Pharmacy Trade and Pingshan Pharmaceutical) and the whole operational assets of Pingshan Pharmaceutical R&D base, through subscribing 15.56% new shares offering under the name of related party Shyndec Pharmaceutical. Correspondingly, the comparative statement of the consolidate profit statement and the consolidate cash flow Statement for this period includes the profit data and the cash flow data of same period last year under the name of above mentioned three companies.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board of

Sinopharm Group Co. Ltd.

Li Zhiming

Chairman

Shanghai, the PRC 25 October 2017

As at the date of this announcement, the executive director of the Company is Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qi Yu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Li Dongjiu, Mr. Lian Wanyong and Mr. Wen Deyong; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".